The main cause of the fall was probably due to Novartis and Sequirus businesses not performing to expectations. Subsequently this has been rectified and the two businesses are humming along quite nicely.
- Forums
- ASX - By Stock
- CSL
- Ann: Half Year Results Analyst Presentation
Ann: Half Year Results Analyst Presentation, page-129
-
- There are more pages in this discussion • 62 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CSL (ASX) to my watchlist
|
|||||
Last
$308.56 |
Change
1.960(0.64%) |
Mkt cap ! $149.1B |
Open | High | Low | Value | Volume |
$308.93 | $311.00 | $306.28 | $198.7M | 643.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 859 | $308.38 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$308.65 | 5 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 8 | 307.700 |
1 | 17 | 307.600 |
1 | 200 | 307.500 |
1 | 71 | 307.470 |
2 | 914 | 307.300 |
Price($) | Vol. | No. |
---|---|---|
308.650 | 5 | 1 |
308.700 | 60 | 1 |
308.720 | 914 | 1 |
308.730 | 71 | 1 |
308.750 | 100 | 2 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
CSL (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online